Okazaki fragments, replication fork explain easy

Reading File
Finding Sources
Searching PubMed

"DNA Replication"[MeSH Terms] AND Okazaki

Searching the Web

Okazaki fragments replication fork DNA replication explanation NIH

Replication fork

Imagine DNA as a zipper.
When a cell needs to copy DNA, the zipper opens in one small area. This Y-shaped open area is the replication fork.
  • Helicase is the enzyme that unzips the two DNA strands.
  • Each old strand acts as a template to make a new matching strand.
  • DNA polymerase builds new DNA, but it can add nucleotides only in one direction: 5′ → 3′.
So, at the fork, the cell copies both old DNA strands at once, but in two different ways.
               Helicase opens DNA
                       ↓
Old DNA strand  ========\ 
                         \   ← Replication fork
                          \
Old DNA strand  ===========

Leading strand

One strand is positioned in the easy direction.
DNA polymerase can follow the opening fork and make this new DNA continuously, like writing one long sentence.
This is the leading strand.

Lagging strand and Okazaki fragments

The other strand faces the opposite direction. DNA polymerase still must build only 5′ → 3′, so it cannot make this strand as one continuous piece toward the fork.
Instead, it makes many short DNA pieces away from the fork. These short pieces are called Okazaki fragments.
Later:
  1. Primase lays down a short RNA primer for each fragment.
  2. DNA polymerase extends it to make DNA.
  3. The RNA primers are removed and replaced with DNA.
  4. DNA ligase acts like glue, joining all the fragments into one continuous lagging strand.
Leading strand:   ---------------------------->  continuous

Lagging strand:   <---  <---  <---  <---         short pieces
                  Okazaki fragments
                         ↓
                  DNA ligase joins them

Simple comparison

FeatureLeading strandLagging strand
DNA synthesisContinuousDiscontinuous
Made asOne long pieceMany Okazaki fragments
Needs primersOne main primerMany primers
Final joining by ligaseNot much needed between piecesYes, joins fragments
Key idea: Both new DNA strands are made in the 5′ → 3′ direction. Okazaki fragments are the cell’s solution for copying the strand that runs the “wrong” way at the replication fork.
The NCBI DNA replication overview describes how RNA primers initiate the fragments and DNA ligase joins them. Textbook support: Basic Medical Biochemistry - A Clinical Approach, 6e, lines 4572-4580.

Transcription (prokaryotic & eukaryotic) + inhibitors

Reading File
Finding Sources
Finding Sources
Searching PubMed

"RNA Polymerase"[MeSH Terms] AND transcription inhibitors

Searching the Web

RNA transcription prokaryotes eukaryotes inhibitors alpha amanitin rifampin NIH

Finding Sources
Finding Sources
Finding Sources

Transcription: easy explanation

Transcription means making an RNA copy from a DNA gene.
Think of DNA as a cookbook kept in a library. The cell does not take out the whole book. It copies one recipe, called a gene, into RNA. For protein-making genes, this RNA is mRNA.
Enzyme: RNA polymerase
Direction of RNA synthesis: always 5′ → 3′
Primer needed? No. Unlike DNA polymerase, RNA polymerase can start without a primer.

Basic steps

  1. Initiation
    RNA polymerase binds the promoter, a DNA sequence before the gene, and locally unwinds DNA.
  2. Elongation
    It reads the DNA template strand in the 3′ → 5′ direction and builds complementary RNA 5′ → 3′.
    DNA template: 3′-TACG-5′
    RNA made: 5′-AUGC-3′
    The RNA sequence is nearly the same as the DNA coding strand, except RNA has U (uracil) instead of T (thymine).
  3. Termination
    RNA polymerase reaches a stop signal, releases the RNA, and DNA rewinds.

Prokaryotic transcription

Occurs in the cytoplasm because bacteria have no nucleus.

RNA polymerase

  • Bacteria have one RNA polymerase.
  • It needs a sigma (σ) factor to recognize and bind the promoter.
  • After initiation, sigma usually detaches and the core polymerase continues RNA synthesis.

Promoter sequences

Common bacterial promoter regions:
  • -35 region
  • -10 region, also called the Pribnow box: TATAAT

Important feature

In prokaryotes, transcription and translation occur together.
That means a ribosome can begin translating the mRNA into protein while RNA polymerase is still making that mRNA.

Termination

1. Rho-independent termination
  • Newly made RNA forms a hairpin loop.
  • This is often followed by many U residues.
  • RNA polymerase stops and the RNA is released.
2. Rho-dependent termination
  • Rho (ρ) is an ATP-dependent helicase protein.
  • It moves along RNA, catches the paused RNA polymerase, and releases the RNA transcript.

Eukaryotic transcription

Occurs in the nucleus. RNA must be processed before it leaves the nucleus for translation in the cytoplasm.

RNA polymerases

EnzymeMain product
RNA polymerase IrRNA: 28S, 18S, 5.8S
RNA polymerase IImRNA, miRNA, some snRNA
RNA polymerase IIItRNA, 5S rRNA, other small RNAs
Memory trick:
  • Pol I makes rRNA, except 5S
  • Pol II makes mRNA
  • Pol III makes tRNA and 5S rRNA

Initiation

Eukaryotic RNA polymerases cannot efficiently recognize promoters alone. They need general transcription factors.
For protein-coding genes:
  • TATA box may be present in the promoter.
  • TBP (TATA-binding protein), part of TFIID, binds it.
  • Other transcription factors assemble.
  • Then RNA polymerase II begins transcription.

RNA processing of eukaryotic mRNA

The first RNA product is pre-mRNA. It needs processing:
  1. 5′ cap added
  2. Splicing removes introns and joins exons
  3. 3′ poly-A tail added
Only then does mature mRNA leave the nucleus for translation.

Prokaryotes vs eukaryotes

FeatureProkaryotesEukaryotes
SiteCytoplasmNucleus
RNA polymerasesOneThree main nuclear polymerases
Promoter recognitionSigma factorGeneral transcription factors
RNA processingMinimalCapping, splicing, poly-A tail
Transcription and translationCoupledSeparate
mRNA typeOften polycistronicUsually monocistronic

Inhibitors of transcription

InhibitorTarget / mechanismImportant point
Rifampicin (rifampin)Binds bacterial RNA polymerase β subunit and blocks initiation/very early RNA-chain elongationUsed for tuberculosis; acts on prokaryotic RNA polymerase
Actinomycin D (dactinomycin)Intercalates between DNA base pairs, blocking RNA polymerase movementInhibits transcription in both prokaryotic and eukaryotic cells; used as an anticancer drug
α-AmanitinToxin from Amanita mushrooms; inhibits eukaryotic RNA polymerasesStrongly inhibits RNA pol II, inhibits pol III at higher concentrations; pol I is resistant

High-yield memory lines

  • Rifampicin: bacteria, RNA polymerase β subunit, tuberculosis.
  • Actinomycin D: binds DNA by intercalation.
  • α-Amanitin: mushroom toxin, blocks RNA polymerase II, so mRNA formation falls.
The NCBI RNA polymerase review supports the distinctions between bacterial and eukaryotic polymerases and describes rifampicin, actinomycin D, and alpha-amanitin mechanisms.

Post-transcriptional modifications

Reading File
Finding Sources
Finding Sources
Searching PubMed

"RNA Processing"[MeSH Terms] AND eukaryotic

Searching the Web

post transcriptional modifications mRNA 5 cap poly A splicing NCBI Bookshelf

Post-transcriptional modifications

These are changes made to an RNA molecule after it is transcribed from DNA. In eukaryotes, the initial RNA transcript, called pre-mRNA, is not ready for translation. It must be processed in the nucleus to become mature mRNA.

The three main modifications of eukaryotic mRNA

Pre-mRNA
5′ ─ exon ─ intron ─ exon ─ intron ─ exon ─ 3′

   ↓ 5′ capping + splicing + 3′ polyadenylation

Mature mRNA
5′ cap ─ exon ─ exon ─ exon ─ poly-A tail
ModificationWhat happensMain function
5′ cappingA 7-methylguanosine cap is added to the 5′ endProtects mRNA, helps ribosome bind, assists nuclear export
3′ polyadenylationMany adenine nucleotides are added as a poly-A tailIncreases mRNA stability, export, and translation efficiency
SplicingIntrons are removed and exons are joinedProduces the correct coding sequence for protein synthesis

1. 5′ cap

A 7-methylguanosine (m⁷G) is added to the 5′ end shortly after transcription starts.
  • It has an unusual 5′-to-5′ triphosphate linkage.
  • It protects mRNA from degradation by exonucleases.
  • It helps the mRNA leave the nucleus.
  • It helps the ribosome recognize the mRNA and start translation.
Exam point: The 5′ cap is 7-methylguanosine, not just an ordinary guanosine.

2. 3′ poly-A tail

After the RNA is cleaved near its 3′ end, poly(A) polymerase adds a tail of many adenine residues.
  • This tail is not directly encoded by the DNA template.
  • It binds poly-A-binding proteins.
  • It increases mRNA stability.
  • It promotes export from the nucleus and efficient translation.
When the poly-A tail gradually shortens, the mRNA is more likely to be degraded.
Exception: Replication-dependent histone mRNAs generally do not have a poly-A tail.

3. RNA splicing

Genes often contain:
  • Exons: sequences retained in mature mRNA
  • Introns: intervening sequences removed from pre-mRNA
The spliceosome removes introns and joins exons. It consists of small nuclear ribonucleoproteins, called snRNPs.

High-yield splice-site rule

Most introns follow the:
5′ GU .......... AG 3′
  • Intron begins with GU
  • Intron ends with AG
  • An internal branch-point adenine (A) helps form a lariat-shaped intron during removal.

Alternative splicing

A single pre-mRNA can be spliced in different ways, producing different mature mRNAs and therefore different proteins.
Same gene → different exon combinations → different proteins
This is one reason humans can make far more proteins than the number of protein-coding genes.
A mutation at a splice donor or acceptor site can cause abnormal mRNA and disease. For example, splice-site variants can reduce normal beta-globin mRNA production in some forms of beta-thalassemia.

Other post-transcriptional RNA changes

RNA editing

The RNA sequence itself is changed after transcription.
Examples:
  • C → U editing in apolipoprotein B mRNA can produce apoB-48 instead of apoB-100.
  • A → I editing occurs in some RNAs; inosine is read similarly to guanosine during translation.

Processing of tRNA and rRNA

Post-transcriptional processing is not limited to mRNA.
  • tRNA: trimming of ends, addition of CCA at the 3′ end, base modifications, and sometimes intron removal.
  • rRNA: cleavage of precursor rRNA and chemical modifications, then assembly with proteins into ribosomal subunits.

Regulation by non-coding RNAs

miRNAs can bind target mRNAs and reduce protein production by:
  • Blocking translation
  • Promoting mRNA degradation

Prokaryotes versus eukaryotes

FeatureProkaryotic mRNAEukaryotic mRNA
5′ capUsually absentPresent
Poly-A tailUsually absent as a stabilizing tailPresent, stabilizes mRNA
Introns and splicingRareCommon
Location of processingMinimal processingMainly nucleus
TranslationCan begin during transcriptionBegins after processing and export

One-line memory aid

“Cap, tail, splice.”
  • Cap at 5′ end
  • Tail at 3′ end
  • Splice out introns, join exons
The NCBI RNA processing summary describes the canonical 5′ m7G cap, 3′ polyadenylation, and intron removal by splicing, as well as their roles in translation and RNA stability.

Mutations, point mutation

Reading File
Finding Sources
Finding Sources
Searching PubMed

"Point Mutation"[MeSH Terms]

Searching the Web

point mutations missense nonsense silent frameshift NCBI Bookshelf

Mutations

A mutation is a permanent change in the DNA nucleotide sequence.
Mutations may occur because of:
  • DNA replication errors
  • Radiation, such as UV or ionizing radiation
  • Chemicals or other mutagens
  • Failure of DNA repair mechanisms
They can occur in:
  • Somatic cells: affect the individual, may contribute to cancer, not usually inherited.
  • Germ cells: egg or sperm cells, can be passed to offspring.

Main types of mutations

TypeWhat changes?
Point mutationOne base pair is replaced by another
InsertionOne or more bases are added
DeletionOne or more bases are removed
Frameshift mutationInsertion/deletion shifts the reading frame
Large-scale mutationLarge deletion, duplication, inversion, translocation, etc.

Point mutation

A point mutation is usually a change in a single nucleotide/base pair.
Example:
Normal DNA:     GAA
Mutated DNA:    GTA
                   ↑
              one base changed
Because protein is read in groups of three bases called codons, the effect depends on whether that altered codon changes an amino acid or creates a stop signal.

Types of point mutations by effect

1. Silent mutation

The DNA base changes, but the amino acid remains the same due to redundancy of the genetic code.
mRNA:  GAA  → glutamate
mRNA:  GAG  → glutamate
  • Protein sequence is unchanged.
  • Usually harmless, although it can occasionally affect splicing or mRNA stability.

2. Missense mutation

One base change causes one amino acid to be replaced by another.
Normal mRNA:   GAG  → glutamate
Mutant mRNA:   GUG  → valine
Classic example: sickle cell disease
  • Beta-globin codon 6: GAG → GTG in DNA coding sequence
  • Glutamate is replaced by valine.
The effect can be mild, severe, or absent depending on the amino acid change and its position in the protein.

3. Nonsense mutation

A base change converts an amino-acid codon into a stop codon.
Normal:   UAU → tyrosine
Mutant:   UAA → STOP
  • Translation stops too early.
  • Produces a shortened, usually nonfunctional protein.
Stop codons are: UAA, UAG, UGA.

4. Splice-site mutation

A nucleotide change occurs at the border between an intron and exon.
  • Normal splicing is disrupted.
  • An exon may be skipped or an intron may remain in mature mRNA.
  • It can lead to an abnormal protein or a frameshift.
High-yield rule: most introns begin with GU and end with AG in RNA.

Point mutation by chemical base change

Transition

A base is replaced by a base of the same type:
  • Purine → purine: A ↔ G
  • Pyrimidine → pyrimidine: C ↔ T

Transversion

A base is replaced by a base of a different type:
  • Purine ↔ pyrimidine
  • A/G ↔ C/T

Frameshift mutation

A frameshift occurs when bases are inserted or deleted in a number not divisible by 3.
Normal:      THE CAT ATE THE RAT
Deletion:    THE ATA TET HER AT...
Every codon after the mutation is read incorrectly, often producing an early stop codon.
  • Usually has a more severe effect than a single missense mutation.
  • Insertions or deletions of 3, 6, 9... bases do not shift the reading frame. They add or remove whole amino acid(s).
Example: Duchenne muscular dystrophy can result from frameshift deletions in the DMD gene.

Quick comparison

MutationProtein effect
SilentSame amino acid
MissenseOne amino acid changed
NonsensePremature stop codon
FrameshiftDownstream amino acids altered
Splice-siteAbnormal mRNA processing

Memory trick

Silent = Same
Missense = Mistaken amino acid
Nonsense = No protein completion
Frameshift = Frame changes
The NCBI mutation reference explains that point mutations alter a single base and may be silent, missense, or nonsense, while the NCBI mutagenesis overview describes frameshifts caused by insertions or deletions not divisible by three.

Oncogenes & proto-oncogenes (activation mechanism

Reading File
Finding Sources
Finding Sources
Searching PubMed

"Proto-Oncogenes"[MeSH Terms] AND activation

Searching the Web

proto-oncogenes oncogenes mechanisms of activation gene amplification chromosomal translocation NCI

Proto-oncogenes and oncogenes

Proto-oncogenes

Proto-oncogenes are normal genes that promote controlled cell growth, division, and survival.
They normally encode proteins such as:
  • Growth factors
  • Growth-factor receptors
  • Signal-transduction proteins
  • Nuclear transcription factors
  • Cell-cycle regulators
Example: RAS helps transmit a growth signal from the cell surface to the nucleus.

Oncogenes

An oncogene is an abnormally activated proto-oncogene that drives excessive cell proliferation and can contribute to cancer.
Normal proto-oncogene
        ↓ activating alteration
Oncogene
        ↓
Continuous / excessive growth signal
        ↓
Cancer development
Key concept: oncogenes act by gain of function. One altered allele can be enough to promote a cancer phenotype at the cellular level, so they behave dominantly.

Mechanisms of proto-oncogene activation

1. Point mutation

A base substitution changes the protein so it becomes constantly active or resistant to normal regulation.

Example: RAS mutation

Normally, RAS switches:
RAS-GTP = ON
RAS-GDP = OFF
A mutation in RAS may prevent GTP breakdown, leaving RAS permanently ON. This causes continuous growth signaling.
  • Seen in many cancers, including colon, pancreatic, and lung cancers.

2. Gene amplification

The cell gains many copies of a proto-oncogene.
More copies of the gene → more mRNA → too much growth-promoting protein.

Examples

Gene amplifiedImportant association
ERBB2 / HER2Breast and gastric cancers
N-MYCNeuroblastoma
MDM2Some sarcomas
CCND1 (cyclin D1)Some cancers, often also activated by translocation
Normal:      [MYC]
Amplified:   [MYC] [MYC] [MYC] [MYC] [MYC]
                         ↓
                  excess MYC protein

3. Chromosomal translocation

A piece of one chromosome moves to another chromosome. This can activate a proto-oncogene in two important ways.

A. Promoter/enhancer swapping

The proto-oncogene is moved beside a strong promoter or enhancer, causing excess production of an otherwise normal protein.
Example: Burkitt lymphoma
t(8;14)

MYC gene from chromosome 8
     moves near
immunoglobulin heavy-chain enhancer on chromosome 14
     ↓
too much MYC expression

B. Fusion gene formation

Two separate genes join and create a new fusion protein with abnormal, continuously active function.
Example: Chronic myeloid leukemia, CML
t(9;22) = Philadelphia chromosome

BCR gene + ABL gene
        ↓
BCR-ABL fusion protein
        ↓
constitutively active tyrosine kinase
        ↓
uncontrolled myeloid-cell proliferation

4. Insertional mutagenesis

A viral genome integrates near a proto-oncogene. Its strong viral promoter/enhancer increases transcription of the nearby cellular proto-oncogene.
Viral promoter inserted near proto-oncogene
                    ↓
excess gene transcription
                    ↓
oncogene activation
This mechanism is classically associated with some retroviruses.

5. Increased transcription due to regulatory mutation

A mutation in a gene’s promoter, enhancer, or other regulatory region can increase gene expression without changing the protein’s amino-acid sequence.
Regulatory DNA mutation
        ↓
more transcription
        ↓
more normal growth-promoting protein
        ↓
excess proliferation

High-yield table

Activation mechanismMain resultClassic example
Point mutationHyperactive proteinRAS
Gene amplificationExcess normal proteinHER2, N-MYC
Translocation: enhancer/promoter swapOverexpression of normal proteinMYC, t(8;14), Burkitt lymphoma
Translocation: fusion geneNew abnormal proteinBCR-ABL, t(9;22), CML
Viral insertion / regulatory changeIncreased transcriptionRetroviral activation

Easy mnemonic: “MAPS”

  • Mutation
  • Amplification
  • Promoter/enhancer translocation
  • Splicing/fusion? Better: Structural fusion from translocation
More simply, memorize: Mutation, amplification, translocation.

Proto-oncogene vs tumor suppressor gene

FeatureProto-oncogene / oncogeneTumor suppressor gene
Normal rolePromotes controlled growthRestrains growth, repairs DNA, or triggers apoptosis
Cancer-causing changeActivationLoss/inactivation
Type of mutationGain of functionLoss of function
Alleles usually neededOneUsually both
ExamplesRAS, MYC, HER2, BCR-ABLTP53, RB, APC, BRCA1/2
A textbook summary identifies point mutation, increased expression from translocation or regulatory change, gene fusion, and gene amplification as major ways a proto-oncogene becomes an oncogene. Thompson & Thompson Genetics and Genomics in Medicine, Figure 16.3. The oncogene mechanisms review also outlines these activation routes.

Tumour suppressor genes (p53, Rb)

Reading File
Finding Sources
Finding Sources
Finding Sources
Searching PubMed

"Tumor Suppressor Protein p53"[MeSH Terms] AND retinoblastoma protein

Searching the Web

p53 Rb tumor suppressor genes cell cycle p21 E2F NCI

Tumor suppressor genes

Tumor suppressor genes are the cell’s brakes. They prevent inappropriate cell division, repair DNA damage, or make severely damaged cells undergo apoptosis.
Cancer develops when these protective genes are lost or inactivated.
  • Oncogenes: accelerator stuck ON, gain-of-function
  • Tumor suppressor genes: brakes fail, loss-of-function
Usually, both copies of a tumor suppressor gene need to be inactivated in a cell. This is the two-hit hypothesis.

1. RB gene: governor of the G1 → S checkpoint

  • Gene: RB1
  • Protein: Rb, retinoblastoma protein
  • Main action: stops the cell from entering S phase and copying DNA.

How Rb works

The transcription factor E2F turns on genes needed for DNA synthesis.

When Rb is active

Active Rb (hypophosphorylated)
          ↓ binds
         E2F
          ↓
DNA-synthesis genes remain OFF
          ↓
Cell stays in G1 phase
Rb binds E2F and prevents it from activating S-phase genes. Thus, active Rb blocks the G1-to-S transition.

When the cell should divide

Growth factors activate cyclin D-CDK4/6, which phosphorylates Rb.
Growth factors
      ↓
Cyclin D + CDK4/6
      ↓ phosphorylates
Rb becomes inactive
      ↓ releases
E2F
      ↓
S-phase genes ON
      ↓
G1 → S progression

Loss of RB

If both RB1 alleles are lost or Rb is inactivated, E2F stays free.
Rb lost/inactive → E2F always free → DNA synthesis genes ON → uncontrolled division

Associations

  • Retinoblastoma
  • Osteosarcoma
  • Many other tumors have disruption of the Rb pathway.
In inherited retinoblastoma, a child is born with one defective RB1 allele. A second acquired mutation in a retinal cell can produce tumor. This explains early onset and bilateral/multiple tumors.

2. p53: guardian of the genome

  • Gene: TP53
  • Protein: p53
  • Main action: detects DNA damage and decides whether the cell should pause, repair DNA, or die.
p53 is called the “guardian of the genome.”

Normal response to DNA damage

DNA damage
     ↓
p53 becomes stabilized and activated
     ↓
p53 acts as a transcription factor
     ↓
p21 production increases
     ↓
p21 inhibits cyclin-CDK complexes
     ↓
Rb stays active and bound to E2F
     ↓
G1 → S arrest
This pause gives the cell time to repair DNA.

If the DNA damage is repaired

  • p53 levels fall.
  • The cell-cycle block is removed.
  • The cell can proceed normally.

If DNA damage cannot be repaired

p53 activates pathways leading to:
  • Senescence: permanent cell-cycle arrest
  • Apoptosis: programmed cell death
Important pro-apoptotic p53 targets include BAX, PUMA, and NOXA.
Severe / unrepaired DNA damage
          ↓
p53
     ↙          ↘
senescence     apoptosis

Loss of p53

Without functional p53:
  • DNA damage is not properly halted.
  • The cell does not reliably repair its DNA.
  • Abnormal cells escape apoptosis.
  • Mutations accumulate, increasing cancer risk.
TP53 is among the most frequently altered genes in human cancers.

Li-Fraumeni syndrome

An inherited pathogenic TP53 variant causes Li-Fraumeni syndrome, with a high risk of early cancers, particularly:
  • Sarcomas
  • Breast cancer
  • Brain tumors
  • Leukemia
  • Adrenocortical carcinoma

p53 and Rb together

The p53 pathway uses Rb to enforce a G1/S stop:
DNA damage
   ↓
p53 ↑
   ↓
p21 ↑
   ↓ inhibits CDKs
Rb remains hypophosphorylated and active
   ↓ binds
E2F
   ↓
No S-phase gene transcription
   ↓
Cell-cycle arrest
Key distinction:
  • p53 detects DNA damage and makes the decision.
  • Rb physically blocks the G1 → S transition by binding E2F.

HPV connection

High-risk HPV can inactivate both pathways:
HPV proteinTargetResult
E6p53Promotes p53 degradation, impaired apoptosis and DNA-damage response
E7RbInactivates Rb, releases E2F, promotes S-phase entry
This contributes to cervical cancer and other HPV-associated cancers.

Quick comparison

Featurep53Rb
GeneTP53RB1
NicknameGuardian of the genomeGovernor of cell cycle
Core roleDNA-damage response, arrest, repair, apoptosisBlocks G1 → S transition
Main downstream factorp21E2F
Loss causesDNA-damaged cells survive/divideUncontrolled DNA synthesis
HPV protein that inhibits itE6E7
Textbook support: Robbins & Kumar Basic Pathology, pp. lines 708-718 and 723-733. The NCBI review of E2F-RB-p53 signaling describes p53-mediated p21 induction, RB-E2F control, cell-cycle arrest, and apoptosis.

Molecular basis of cancer / chemical carcinogens

Reading File
Finding Sources
Finding Sources
Finding Sources
Searching PubMed

"Chemical Carcinogenesis"[MeSH Terms] AND mechanisms

Searching the Web

chemical carcinogens initiation promotion direct acting indirect acting NCBI Bookshelf

Molecular basis of cancer

Cancer develops through the accumulation of genetic and epigenetic changes that give a cell a growth and survival advantage.
A normal cell becomes cancerous when it gains growth signals, loses growth brakes, avoids death, and accumulates further mutations.

Major gene groups involved

Gene groupNormal functionCancer-causing changeExamples
Proto-oncogenesPromote controlled growthGain-of-function activationRAS, MYC, HER2, BCR-ABL
Tumor suppressor genesStop growth, repair damage, trigger apoptosisLoss-of-functionTP53, RB, APC, BRCA1/2
Apoptosis-regulating genesEliminate damaged cellsReduced apoptosisBCL2 overexpression, TP53 loss
DNA-repair genesCorrect DNA damageGenomic instabilityBRCA1/2, mismatch-repair genes
Telomerase-related pathwaysLimit cellular lifespanTelomerase reactivation allows limitless divisionTERT activation

What cancer cells acquire

  1. Self-sufficient growth signaling
    Example: activated RAS or HER2.
  2. Resistance to growth inhibition
    Example: loss of Rb or p53.
  3. Evasion of apoptosis
    Example: BCL2 overexpression or p53 loss.
  4. Replicative immortality
    Cancer cells often activate telomerase, preventing progressive telomere shortening.
  5. Angiogenesis
    Tumors induce blood-vessel growth, often through VEGF, to obtain oxygen and nutrients.
  6. Invasion and metastasis
    Cells lose normal adhesion, degrade extracellular matrix, enter vessels, and colonize distant sites.
  7. Genomic instability
    Defective DNA repair allows mutations to accumulate faster.
  8. Immune evasion
    Tumors may suppress or escape immune recognition, for example through PD-L1 signaling.

Chemical carcinogens

Chemical carcinogens cause cancer mainly by producing DNA damage. Many form covalent DNA lesions called DNA adducts. If this damage is not repaired before replication, permanent mutations can result.
Chemical exposure
       ↓
DNA adduct / DNA damage
       ↓
Mutation in oncogene or tumor-suppressor gene
       ↓
Abnormal cell survival and proliferation
       ↓
Cancer

Types of chemical carcinogens

1. Direct-acting carcinogens

These are already active and do not need metabolic activation.
  • Often electrophilic compounds that directly damage DNA.
  • Important examples include some alkylating agents used in chemotherapy.
  • They can cause therapy-related cancers, especially leukemia, after a latent period.
Direct-acting chemical → directly reacts with DNA

2. Indirect-acting carcinogens, or procarcinogens

These need conversion by the body, often in the liver, into an active ultimate carcinogen.
  • Commonly activated by the cytochrome P450 enzyme system.
  • Individual variation in these enzymes can influence susceptibility.
Procarcinogen
     ↓ CYP450 metabolism
Ultimate carcinogen
     ↓
DNA damage / mutation

Important examples and associations

CarcinogenCommon sourceImportant cancer association
Benzo[a]pyrene and other polycyclic aromatic hydrocarbonsTobacco smoke, soot, coal tar, charred foodsLung cancer and other smoking-related cancers
Aflatoxin B1Mold-contaminated peanuts/grains, Aspergillus flavusHepatocellular carcinoma, often linked with TP53 mutation
Aromatic amines and azo dyesDye, rubber, leather, chemical industriesUrothelial carcinoma of urinary bladder
β-naphthylamineIndustrial aromatic amine exposureBladder carcinoma
Vinyl chloridePVC industry exposureHepatic angiosarcoma
ArsenicContaminated water, pesticides, industrial exposureSkin cancer, lung cancer, angiosarcoma
AsbestosConstruction/insulation exposureMesothelioma and bronchogenic carcinoma
Nitrosamines / nitrosamidesSome preserved foods, tobacco-related exposureGastric and other gastrointestinal cancers
Alkylating agentsChemotherapyTherapy-related acute myeloid leukemia / myelodysplastic syndrome
Important distinction: asbestos is usually grouped as a carcinogenic environmental exposure, but it acts through chronic inflammation, reactive oxygen species, and physical fiber effects rather than fitting neatly into the classic direct DNA-binding chemical-carcionogen model.

Initiation, promotion, and progression

Chemical carcinogenesis is classically explained in three stages.

1. Initiation

An initiator causes permanent, nonlethal DNA damage.
  • It is generally irreversible.
  • The damage becomes fixed as a mutation when the cell divides.
  • An initiator alone may not be enough to produce a tumor.
Initiator → DNA mutation → initiated cell

2. Promotion

A promoter causes proliferation of the previously initiated cells.
  • Promoters are generally not directly mutagenic.
  • They stimulate cell proliferation, survival, inflammation, or altered signaling.
  • Promotion usually requires repeated or sustained exposure.
  • It is relatively reversible early on if exposure stops.
Classic promoter: phorbol esters, such as TPA, which activate protein kinase C.
Initiated cell
      + repeated promoter exposure
      ↓
clonal expansion
      ↓
preneoplastic lesion

3. Progression

Further mutations accumulate, producing increasingly malignant behavior:
  • Faster growth
  • Resistance to apoptosis
  • Angiogenesis
  • Invasion
  • Metastasis
  • Treatment resistance
Initiation → Promotion → Progression → Malignant cancer

High-yield comparison

FeatureInitiatorPromoter
Directly damages DNA?Yes, usuallyNo, usually
Causes mutation?YesNo direct mutation
Effect reversible?NoOften reversible early
Exposure requiredOften single exposure can initiateRepeated exposure usually needed
Main actionProduces initiated mutant cellExpands the initiated clone

Easy memory line

Initiator mutates; promoter multiplies.
Chemical carcinogens may damage DNA directly or after metabolic activation, while promoters expand mutated cell clones and allow further mutations to accumulate. Robbins & Kumar Basic Pathology, Chemical and Radiation Carcinogenesis, lines 850-858; Robbins, Cotran & Kumar Pathologic Basis of Disease, Chemical Carcinogenesis, lines 3218-3224. The NCBI carcinogenesis overview also describes initiation as persistent DNA injury and promotion as a proliferation-enhancing stage.

PCR / RT-PCR

Reading File
Finding Sources
Finding Sources
Searching PubMed

"Polymerase Chain Reaction"[MeSH Terms] AND "Reverse Transcriptase Polymerase Chain Reaction"

Searching the Web

PCR RT-PCR reverse transcription PCR steps denaturation annealing extension NCBI Bookshelf

PCR

PCR = Polymerase Chain Reaction
It is a laboratory technique used to make millions of copies of a specific DNA sequence.
Think of it as a DNA photocopier.

Ingredients needed

  • Template DNA containing the target sequence
  • Two primers: short DNA sequences that mark the target region
  • Taq polymerase: heat-stable DNA polymerase
  • dNTPs: A, T, G, C building blocks
  • Buffer and Mg²⁺

Three steps in each PCR cycle

StepTemperature, approximateWhat happens
Denaturation94-95°CDouble-stranded DNA separates into two single strands
Annealing50-65°CPrimers bind to complementary target sequences
Extension72°CTaq polymerase extends primers and makes new DNA strands
Double-stranded DNA
        ↓ heat
Two single DNA strands
        ↓ cooling
Primers attach
        ↓ Taq polymerase
New DNA copies made
This is repeated about 25-40 cycles.
1 DNA target → 2 → 4 → 8 → 16 → ...
So the target DNA rises exponentially, approximately 2ⁿ copies after n cycles.

Uses of PCR

  • Detecting infections with DNA-containing organisms
  • Detecting mutations and inherited disorders
  • Forensic testing and paternity testing
  • DNA sequencing and cloning
  • Cancer mutation testing

RT-PCR

Usually, RT-PCR means reverse-transcription PCR.
It is used when the starting material is RNA, not DNA.

Principle

RNA cannot be directly amplified by ordinary PCR because PCR requires DNA as the template.
So, first, the enzyme reverse transcriptase converts RNA into complementary DNA (cDNA). Then ordinary PCR amplifies that cDNA.
RNA
 ↓ reverse transcriptase
cDNA
 ↓ PCR
Millions of DNA copies

Steps

  1. Extract RNA from the sample.
  2. Use reverse transcriptase to make cDNA.
  3. Amplify the cDNA using standard PCR cycles:
    • Denaturation
    • Annealing
    • Extension

Uses of reverse-transcription PCR

  • Detecting RNA viruses, such as influenza or SARS-CoV-2
  • Measuring gene expression through mRNA detection
  • Detecting RNA fusion transcripts, such as BCR-ABL in chronic myeloid leukemia

PCR vs RT-PCR

FeaturePCRRT-PCR, reverse-transcription PCR
Starting materialDNARNA
Extra enzyme neededNoYes, reverse transcriptase
First productAmplified DNAcDNA, then amplified DNA
Main useDetect DNA sequencesDetect RNA viruses or RNA expression

RT-PCR versus real-time PCR: common confusion

These terms are often confused.
  • RT-PCR = Reverse-transcription PCR: RNA → cDNA → PCR.
  • Real-time PCR / qPCR = PCR product is measured during every cycle using fluorescence.
  • Real-time RT-PCR / RT-qPCR = RNA is first converted to cDNA, then amplified and measured in real time. This is widely used for RNA-virus testing.
RT-PCR:     RNA → cDNA → endpoint PCR result

qPCR:       DNA → PCR + fluorescence-based quantification

RT-qPCR:    RNA → cDNA → real-time fluorescent PCR

High-yield line

PCR amplifies DNA. RT-PCR first converts RNA to cDNA, then amplifies it.
The NCBI PCR overview describes the denaturation, annealing, and extension cycle, while Tietz Textbook of Laboratory Medicine, “Reverse Transcriptase-Polymerase Chain Reaction,” explains that reverse transcriptase converts RNA targets into cDNA before PCR.

Southern, Western, Northern blotting

Reading File
Finding Sources
Finding Sources
Searching the Web

Southern Northern Western blot differences DNA RNA protein NCBI Bookshelf

Your credits are exhausted. You can purchase a top-up or subscribe to a plan to continue using Orris. If you're already subscribed, your daily credits will reset tomorrow.
This is a shared conversation. Sign in to Orris to start your own chat.